R Schennach-Wolff

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial
    Rebecca Schennach
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336, Munich, Germany
    Psychiatr Q 83:187-207. 2012
  2. doi request reprint Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder
    Rebecca Schennach-Wolff
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, 80336 Munich, Germany
    J Psychiatr Res 45:1639-47. 2011
  3. pmc Is the PANSS used correctly? a systematic review
    Michael Obermeier
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, Munich, Germany
    BMC Psychiatry 11:113. 2011
  4. doi request reprint Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Eur Neuropsychopharmacol 21:370-8. 2011
  5. ncbi request reprint Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Munich, Germany
    J Clin Psychopharmacol 30:726-31. 2010
  6. doi request reprint Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Acta Psychiatr Scand 123:228-38. 2011
  7. doi request reprint A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Pharmacopsychiatry 43:245-51. 2010
  8. doi request reprint An early improvement threshold to predict response and remission in first-episode schizophrenia
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Nussbaumstrasse 7, Muenchen 80336, Germany
    Br J Psychiatry 196:460-6. 2010
  9. doi request reprint Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Psychiatry 26:284-92. 2011
  10. doi request reprint Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    World J Biol Psychiatry 11:729-38. 2010

Detail Information

Publications24

  1. doi request reprint Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial
    Rebecca Schennach
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336, Munich, Germany
    Psychiatr Q 83:187-207. 2012
    ..0113) were found to be significantly predictive of recovery. Our results underline the need to implement more specific treatment strategies to improve long-term outcome...
  2. doi request reprint Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder
    Rebecca Schennach-Wolff
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, 80336 Munich, Germany
    J Psychiatr Res 45:1639-47. 2011
    ..To examine the influencing factors and predictors of early improvement in schizophrenia patients...
  3. pmc Is the PANSS used correctly? a systematic review
    Michael Obermeier
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, Munich, Germany
    BMC Psychiatry 11:113. 2011
    ..ratio scale) leads to a set of mathematical problems, potentially resulting in erroneous results concerning the efficacy of the treatment...
  4. doi request reprint Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Eur Neuropsychopharmacol 21:370-8. 2011
    ..To evaluate the predictive validity of early response compared to other well-known predictor variables in acutely ill first-episode patients...
  5. ncbi request reprint Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Munich, Germany
    J Clin Psychopharmacol 30:726-31. 2010
    ..Furthermore, these linking results were compared with those derived from randomized controlled trials to examine if the baseline severity might influence the linking results...
  6. doi request reprint Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Acta Psychiatr Scand 123:228-38. 2011
    ..To examine depressive symptoms, their course during treatment, and influence on outcome...
  7. doi request reprint A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Pharmacopsychiatry 43:245-51. 2010
    ..The aim of this paper is to apply the proposed consensus remission criteria to an acutely ill inpatient sample at admission and evaluate their adaptability in this patient population and pharmaceutical trials...
  8. doi request reprint An early improvement threshold to predict response and remission in first-episode schizophrenia
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Nussbaumstrasse 7, Muenchen 80336, Germany
    Br J Psychiatry 196:460-6. 2010
    ..Early improvement with treatment is thought to be important in patients with first-episode schizophrenia, yet a valid definition is still outstanding...
  9. doi request reprint Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Psychiatry 26:284-92. 2011
    ..Purpose of this study was to assess subjective well-being in schizophrenia inpatients and to find variables predictive for response and remission of subjective well-being...
  10. doi request reprint Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    World J Biol Psychiatry 11:729-38. 2010
    ..To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome...
  11. doi request reprint Attitude towards adherence in patients with schizophrenia at discharge
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Nussbaumstr 7, 80336 Munich, Germany
    J Psychiatr Res 43:1294-301. 2009
    ....
  12. doi request reprint Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders
    Rebecca Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Schizophr Res 113:210-7. 2009
    ..To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group...
  13. doi request reprint Outcome of suicidal patients with schizophrenia: results from a naturalistic study
    R Schennach-Wolff
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Acta Psychiatr Scand 121:359-70. 2010
    ..Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences...
  14. doi request reprint Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients
    M Jager
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, D 80336 Munich, Germany
    Schizophr Res 118:183-8. 2010
    ..To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions...
  15. doi request reprint Effect of aripiprazole on cognition in the treatment of patients with schizophrenia
    M Riedel
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
    Pharmacopsychiatry 43:50-7. 2010
    ..The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia...
  16. doi request reprint The validity of self-rated psychotic symptoms in depressed inpatients
    F Seemüller
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Psychiatry 27:547-52. 2012
    ..Self-ratings of psychotic experiences might be biased by depressive symptoms...
  17. doi request reprint The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia
    M Riedel
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstr 7, 80336, Munich, Germany
    Qual Life Res 20:263-72. 2011
    ..To develop and evaluate a self- and observer-rating scale on quality of life in patients suffering from schizophrenia with regard to the efficacy of atypical antipsychotics based on different dimensions and to apply within a pilot study...
  18. doi request reprint Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone
    M Riedel
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Munich, Germany
    Hum Psychopharmacol 25:116-25. 2010
    ..To examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment...
  19. doi request reprint [Bipolar depression. Spectrum of clinical pictures and differentiation from unipolar depression]
    F Seemüller
    Klinik fur Psychiatrie und Psychotherapie, LMU Munchen, Nussbaumstrasse 7, 80336, Munchen, Deutschland
    Nervenarzt 81:531-8. 2010
    ..Therefore we propose to assess the risk of each patient for having bipolar disorder individually. Patients who are at a high risk should at least be informed and should be closely monitored for the development of manic episodes...
  20. doi request reprint Safety evaluation of zotepine for the treatment of schizophrenia
    Michael Riedel
    Ludwig Maximilians University Munich, Department of Psychiatry and Psychotherapy, Munich, Germany
    Expert Opin Drug Saf 9:659-66. 2010
    ..Zotepine is an antipsychotic with atypical properties and previous data have suggested a very favorable side effect profile...
  21. doi request reprint Does early improvement in major depression protect against treatment emergent suicidal ideation?
    Florian Seemüller
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, Munich, Germany
    J Affect Disord 124:183-6. 2010
    ..To investigate the association of early improvement and treatment emergent suicidal ideation in a large sample (N=705) of naturalistically treated inpatients with major depressive disorder...
  22. pmc Should the PANSS be rescaled?
    Michael Obermeier
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    Schizophr Bull 36:455-60. 2010
    ..Even significance levels of estimated treatment effects change, depending on the structure of the data (eg, baseline symptom severity). Using a PANSS version with items ranging from 0 to 6 would avoid such often neglected pitfalls...
  23. doi request reprint Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
    Norbert Muller
    Department of Psychiatry and Psychotherapy, Ludwig Maximilians Universitat Munchen, Germany
    Schizophr Res 121:118-24. 2010
    ..In future, further trials are needed to investigate the effect of COX-2 inhibitors on prodromal and negative symptoms of schizophrenia...
  24. doi request reprint Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials
    Florian Seemüller
    Department of Psychiatry and Psychotherapy, Ludwig Maximilian University Munich, Munich, Germany
    J Clin Psychiatry 71:1425-33. 2010
    ..Because of strict inclusion and exclusion criteria, results drawn from placebo-controlled randomized antidepressant efficacy trials may not be transferable to real-world patients...